| 2025-10-29 |
详情>>
股本变动：
变动后总股本13103.46万股
|
| 2025-10-29 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.06美元,归母净利润918.90万美元,同比去年增长-29.99%
|
| 2025-10-20 |
股东大会：
将于2025-11-10召开股东大会
会议内容 ▼▲
- 1.A proposal to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock, par value $0.001 per share (the “Common Stock”) (A) underlying (i) shares of Series H convertible preferred stock, par value $0.001 per share (the “Series H Preferred Stock”) and warrants (the “Investor Warrants”) issued by us to investors pursuant to the terms of that certain Securities Purchase Agreement, dated as of September 2, 2025, by and among the Company and the investors party thereto, (ii) warrants issued by us pursuant to the terms of (a) that certain engagement letter, dated August 27, 2025, between the Company and Rodman & Renshaw LLC, and (b) that certain engagement letter, dated August 28, 2025, between the Company and GP Nurmenkari Inc. (collectively, the “Placement Agent Warrants”), (iii) shares of Series I convertible preferred stock, par value $0.001 per share (the “Series I Preferred Stock”), issued by us pursuant to that certain Membership Interest Purchase Agreement, dated as of September 2, 2025, by and among the Company, LPU Holdings LLC (“LPU”) and the members of LPU identified on the signature pages attached thereto, and (iv) warrants issued by us pursuant to the terms of that certain consulting agreement, dated as of October 1, 2025, by and among the Company, James Altucher and Z-List Media, Inc. (the “Consulting Warrants” and, together with the Investor Warrants and Placement Agent Warrants, the “Warrants”), and (B) to be issued pursuant to (i) that certain engagement letter, dated as of August 31, 2025, by and between the Company and Palladium Capital Group, LLC (the “Advisory Shares”), and (ii) the MIPA upon the achievement of certain milestone events (such shares, the “Milestone Shares”), including shares of Common Stock issuable upon certain warrants to be issued upon achievement of such milestone events (the “Milestone Warrants”), in an amount equal to or in excess of 20% of our Common Stock outstanding immediately prior to the issuance of such Series H Preferred Stock, Series I Preferred Stock, Warrants, Advisory Shares, Milestone Shares and Milestone Warrants (including any issuance of shares of Common Stock upon the operation ofanti-dilution provisions applicable to the Series H Preferred Stock, Series I Preferred Stock and Warrants in accordance with their terms) (the “Issuance Proposal”);
2.A proposal to approve the Second Amendment (the “Amendment”) to the Q/C Technologies, Inc. 2021 Equity Incentive Plan (as amended, the “Plan”), to increase the total number of shares of the Company’s Common Stock authorized for issuance under such Plan by 1,375,000, to a total of 1,400,000 shares (“Incentive Plan Amendment Proposal”);
3.A proposal to approve an amendment to our Certificate of Incorporation, as amended (the “Charter”), to effect, at the discretion of the board of directors (the “Board”) of the Company but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Special Meeting, a reverse stock split of all of the outstanding shares of Common Stock, at a ratio in the range of 1-for-2 to 1-for-250, with such ratio to be determined by the Board in its discretion and included in a public announcement (the “Reverse Stock Split Proposal”);
4.A proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Issuance Proposal, the Incentive Plan Amendment Proposal or Reverse Stock Split Proposal (the “Adjournment Proposal”).
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益0.02美元,归母净利润357.10万美元,同比去年增长-24.21%
|
| 2025-07-29 |
财报披露：
美东时间 2025-07-29 盘后发布财报
|
| 2025-06-11 |
详情>>
内部人交易：
Livingston Reginald共交易2笔
|
| 2025-04-30 |
详情>>
业绩披露：
2025年一季报每股收益0.01美元,归母净利润160.80万美元,同比去年增长-50.81%
|
| 2025-04-21 |
股东大会：
将于2025-05-20召开股东大会
会议内容 ▼▲
- 1.A proposal to elect six directors to hold office for a one-year term and until their successors are elected and qualified or until their earlier incapacity, removal or resignation (the “Election of Directors”);
2.A proposal to ratify the appointment of Stephano Slack LLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 (the “Auditor Ratification Proposal”);
3.A proposal to approve an amendment to our Certificate of Incorporation, as amended (the “Charter”), to effect, at the discretion of the board of directors (the “Board”) of the Company but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of our common stock, par value $0.001 per share, at a ratio in the range of 1-for-2 to 1-for-100, with such ratio to be determined by the Board in its discretion and included in a public announcement (the “Reverse Stock Split Proposal”);
4.A proposal to approve an amendment to the Charter to increase the number of our authorized shares of Common Stock from 250,000,000 shares to 1,250,000,000 shares and to make a corresponding change to the number of authorized shares of capital stock (the “Share Increase Proposal”);
5.A proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Election of Directors, the Auditor Ratification Proposal, the Reverse Stock Split Proposal or the Share Increase Proposal (the “Adjournment Proposal”).
|
| 2025-03-25 |
股东大会：
将于2025-05-08召开股东大会
会议内容 ▼▲
- 1.The election of eight individuals as Trustees, each to hold office until the next annual meeting of shareholders and until their successors are duly elected and qualify;
2.The ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025;
3.The approval, on a non-binding advisory basis, of the compensation of the Company’s Named Executive Officers as disclosed in the accompanying Proxy Statement;
4.Such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2025-02-14 |
详情>>
业绩披露：
2022年年报每股收益-0.38美元,归母净利润-3544.5万美元,同比去年增长-250.52%
|
| 2025-02-14 |
详情>>
业绩披露：
2024年年报每股收益0.19美元,归母净利润2165.00万美元,同比去年增长8.94%
|
| 2024-11-01 |
股东大会：
将于2024-11-25召开股东大会
会议内容 ▼▲
- 1.A proposal to elect seven (7) directors to hold office for a one year term and until their successors are elected and qualified or until their earlier incapacity, removal or resignation (the “Election of Directors”);
2.A proposal to approve a proposed amendment to the TNF Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the aggregate number of shares available for the grant of awards by 2,259,060 shares, to a total of 2,500,000 shares of common stock (the “Incentive Plan Amendment Proposal”);
3.A proposal to ratify the appointment of Stephano Slack LLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (the “Auditor Ratification Proposal”);
4.A proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Election of Directors, the Incentive Plan Amendment Proposal or the Auditor Ratification Proposal (the “Adjournment Proposal”);
5.Such other matters as may properly come before the Annual Meeting or any adjournment(s) or postponement(s) thereof.
|
| 2024-10-28 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.12美元,归母净利润1312.60万美元,同比去年增长-38.11%
|
| 2024-07-31 |
详情>>
业绩披露：
2023年中报每股收益0.23美元,归母净利润2263.60万美元,同比去年增长37.49%
|
| 2024-07-31 |
详情>>
业绩披露：
2024年中报每股收益0.04美元,归母净利润471.20万美元,同比去年增长-79.18%
|
| 2024-07-01 |
股东大会：
将于2024-07-24召开股东大会
会议内容 ▼▲
- 1.A proposal to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying (i) shares of Series F-1 convertible preferred stock and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated as of May 20, 2024, by and among the Company and the investors named therein (the “Series F-1 Purchase Agreement”), in an amount equal to or in excess of 20% of our common stock outstanding immediately prior to the issuance of such Series F-1 convertible preferred stock and warrants (including any amortization payments made to the holders of the Series F-1 convertible preferred stock in the form of issuance of shares of common stock and upon the operation of anti-dilution provisions applicable to such Series F-1 convertible preferred stock and warrants in accordance with their terms), (ii) shares of Series G convertible preferred stock and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated as of May 20, 2024, by and among the Company and the investors named therein (the “Series G Purchase Agreement”), in an amount equal to or in excess of 20% of our common stock outstanding immediately prior to the issuance of such Series G convertible preferred stock and warrants (including any dividend payments made “in kind” in the form of additional shares of Series G convertible preferred stock and upon the operation of anti-dilution provisions applicable to such Series G convertible preferred stock and warrants in accordance with their terms), (iii) warrants issued by us pursuant to the terms of that certain engagement agreement, by and between the Company and Palladium Capital Group, LLC, in an amount equal to or in excess of 20% of our common stock outstanding immediately prior to the issuance of such warrants (including upon the operation of anti-dilution provisions applicable to such warrants in accordance with its terms), and (iv) warrants issued by us pursuant to the terms of that certain engagement agreement, by and between the Company and GP Nurmenkari Inc., in an amount equal to or in excess of 20% of our common stock outstanding immediately prior to the issuance of such warrants (including upon the operation of anti-dilution provisions applicable to such warrants in accordance with its terms) (the “Issuance Proposal”);
2.A proposal to approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of common stock from 16,666,666 to 250,000,000 and to make a corresponding change to the number of authorized shares of capital stock (the “Share Increase Proposal”);
3.A proposal to ratify the appointment of Morison Cogen LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (the “Auditor Ratification Proposal”);
4.A proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Issuance Proposal, the Share Increase Proposal or the Auditor Ratification Proposal (the “Adjournment Proposal”);
5.Such other matters as may properly come before the Special Meeting or any adjournment(s) or postponement(s) thereof.
|
| 2024-04-30 |
详情>>
业绩披露：
2024年一季报每股收益0.03美元,归母净利润326.90万美元,同比去年增长-75.53%
|
| 2024-03-22 |
股东大会：
将于2024-05-02召开股东大会
会议内容 ▼▲
- 1.The election of eight individuals as Trustees, each to hold office until the next annual meeting of shareholders and until their successors are duly elected and qualify;
2.The ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024;
3.The approval, on a non-binding advisory basis, of the compensation of the Company’s Named Executive Officers as disclosed in the accompanying Proxy Statement;
4.Such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2024-02-16 |
详情>>
业绩披露：
2023年年报每股收益0.20美元,归母净利润1987.30万美元,同比去年增长156.07%
|
| 2023-10-31 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.21美元,归母净利润2121.00万美元,同比去年增长153.80%
|
| 2023-06-30 |
股东大会：
将于2023-07-31召开股东大会
会议内容 ▼▲
- 1.A proposal to elect six (6) directors to hold office for a one year term and until their successors are elected and qualified or until their earlier incapacity, removal or resignation (the “Election of Directors”);
2.A proposal to approve the Agreement and Plan of Merger (the “Plan of Merger”) between the Company and its wholly-owned Delaware subsidiary, MyMD Pharmaceuticals, Inc. (“MyMD Delaware”), pursuant to which the Company will merge with and into MyMD Delaware for the sole purpose of changing the Company’s state of domicile, including the approval of the Certificate of Incorporation of MyMD Delaware (the “Reincorporation Proposal”);
3.A proposal to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying shares of convertible preferred stock and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated February 21, 2023, by and among MyMD Pharmaceuticals, Inc. and the investors named therein, in an amount equal to or in excess of 20% of our common stock outstanding immediately prior to the issuance of such convertible preferred stock and warrants (including upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants) (the “Issuance Proposal”);
4.A proposal to ratify the appointment of Morison Cogen LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (the “Auditor Ratification Proposal”);
5.A proposal to approve, on an advisory basis, the compensation paid to our named executive officers (the “Say-on-Pay Proposal”);
6.Such other matters as may properly come before the Annual Meeting or any adjournment(s) or postponement(s) thereof.
|
| 2023-03-24 |
股东大会：
将于2023-05-04召开股东大会
会议内容 ▼▲
- 1.The election of nine individuals as Trustees, each to hold office until the next annual meeting of shareholders and until their successors are duly elected and qualify;
2.The ratification of the appointment of BDO USA, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023;
3.The approval, on a non-binding advisory basis, of the compensation of Named Executive Officers as disclosed in the Company’s 2023 Proxy Statement in accordance with the compensation rules of the Securities and Exchange Commission;
4.The approval of the Amended and Restated Acadia Realty Trust 2020 Share Incentive Plan;
5.The approval, on a non-binding advisory basis, of whether the shareholder vote to approve the compensation of the Named Executive Officers should occur every one, two or three years;
6.Such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2023-03-13 |
股东大会：
将于2023-04-20召开股东大会
会议内容 ▼▲
- 1.A proposal to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying shares of convertible preferred stock and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated February 21, 2023, by and among MyMD Pharmaceuticals, Inc. and the investors named therein, in an amount equal to or in excess of 20% of our common stock outstanding immediately prior to the issuance of such convertible preferred stock and warrants (including upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants) (the “Issuance Proposal”);
2.A proposal to approve an amendment to our Restated Certificate of Incorporation to define the threshold required to achieve a quorum at a meeting of the Company’s stockholders as one third of the shares entitled to vote at such meeting (the “Charter Amendment Proposal”);
3.A proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Issuance Proposal or the Charter Amendment Proposal;
4.Such other matters as may properly come before the Special Meeting or any adjournment(s) or postponement(s) thereof.
|
| 2022-10-26 |
股东大会：
将于2022-12-14召开股东大会
会议内容 ▼▲
- 1.Election of six (6) directors to hold office for a one year term and until their successors are elected and qualified or until their earlier incapacity, removal or resignation;
2.Ratification of the appointment of Morison Cogen LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.Such other matters as may properly come before the Annual Meeting or any adjournment(s) or postponement(s) thereof.
|
| 2022-03-25 |
股东大会：
将于2022-05-05召开股东大会
会议内容 ▼▲
- 1.The election of nine Trustees to hold office until the next Annual Meeting and until their successors are duly elected and qualify;
2.The ratification of the appointment of BDO USA, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2022;
3.The approval, on a non-binding advisory basis, of the compensation of Named Executive Officers as disclosed in the Company's 2022 Proxy Statement in accordance with the compensation rules of the Securities and Exchange Commission;
4.Such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2021-11-22 |
股东大会：
将于2021-12-29召开股东大会
会议内容 ▼▲
- 1.Election of six (6) directors to hold office for a one year term and until their successors are elected and qualified or until their earlier incapacity, removal or resignation;
2.Ratification the appointment of Morison Cogen LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.Such other matters as may properly come before the Annual Meeting or any adjournment(s) or postponement(s) thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-25 |
股东大会：
将于2021-05-06召开股东大会
会议内容 ▼▲
- 1.The election of nine Trustees to hold office until the next Annual Meeting and until their successors are duly elected and qualify;
2.The ratification of the appointment of BDO USA, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2021;
3.The approval, on a non-binding advisory basis, of the compensation of Named Executive Officers as disclosed in the Company's 2021 Proxy Statement in accordance with the compensation rules of the Securities and Exchange Commission;
4.The approval of the Company’s 2021 Employee Share Purchase Plan;
5.Such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2021-03-23 |
股东大会：
将于2021-04-15召开股东大会
会议内容 ▼▲
- 1.The Share Issuance Proposal-to approve, for purposes of complying with Nasdaq Listing Rule 5635(a), the issuance of shares of our common stock to MYMD stockholders as merger consideration in the merger of XYZ Merger Sub Inc., a Florida corporation and a wholly owned subsidiary of Akers (“Merger Sub”), with and into MyMD Pharmaceuticals, Inc., a Florida corporation (“MYMD”), including potential milestone payments in shares of our common stock up to the number of merger consideration shares issued by Akers to MYMD stockholders at the closing of the merger (“Milestone Shares”) payable upon achievement of certain market capitalization milestone events during the 36-month period immediately following the closing of the merger (the “Milestone Period”), pursuant to the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November 11, 2020, as amended, by and among Akers, Merger Sub and MYMD (the “Merger Agreement”), the Merger Agreement and the transactions contemplated thereby (the “Share Issuance Proposal”);
2.The Reverse Stock Split Proposal-to approve an amendment to the amended and restated certificate of incorporation of the combined company, which will be in effect at the effective time of the merger (the “A&R Charter”) to effect a reverse stock split at the discretion of the Akers Board of Directors with a ratio between 1-for-1.5 and 1- for-20 with respect to the issued and outstanding common stock of the combined company immediately following the merger (the “Reverse Stock Split Proposal”);
3.The A&R Charter Proposal-to approve the amendment and restatement of our certificate of incorporation in its entirety which will be in effect at the effective time of the merger (the “A&R Charter Proposal”);
4.The Incentive Plan Proposal-to approve the Akers Biosciences, Inc. 2021 Equity Incentive Plan (the “Incentive Plan Proposal”).
5.The Akers Golden Parachute Compensation Proposal-to approve, on a non-binding advisory basis, the compensation that may be paid or become payable to Akers’ named executive officers in connection with the merger (the “Akers Golden Parachute Compensation Proposal”);
6.The Contribution Proposal-to approve the contribution to Oravax Medical Inc. (“Oravax”) of (a) an amount in cash equal to $1,500,000, and, (b) cause Cystron Biotech, LLC (“Cystron”) to assign to Oravax substantially all of its assets, including the Amended and Restated License Agreement, dated March 19, 2020, between Cystron and Premas whereby Premas granted Cystron, amongst other things, an exclusive license with respect to Premas’ vaccine platform for the development of a vaccine against SARS-CoV-2, (the “License Agreement”), in exchange for a number of shares of Oravax’s capital stock equivalent to 13% of Oravax’s then outstanding capital stock on a fully diluted basis (the “Contribution Proposal”) pursuant to the Contribution and Assignment Agreement, dated March 18, 2021, by and among Akers, Cystron, and Oravax, as it may be amended from time to time (the “Contribution and Assignment Agreement”);
7.The Adjournment Proposal-to consider and vote upon a proposal to adjourn the special meeting to a later date or dates, if necessary, to permit the solicitation of additional proxies if, based upon the tabulated vote at the time of the special meeting, there are not sufficient votes to approve one or more proposals presented to stockholders for vote (the “Adjournment Proposal”).
|
| 2020-07-29 |
股东大会：
将于2020-08-27召开股东大会
会议内容 ▼▲
- 1.Approval, pursuant to Nasdaq listing rule 5635(a), of the issuance of shares of our common stock upon conversion of Series D Convertible Preferred Stock (the “Series D Preferred Stock”) in excess of 20% of our common stock outstanding;
2.Approval, pursuant to Nasdaq listing rule 5635(a), of the potential issuance of our common stock in excess of 20% of our common stock outstanding in connection with milestone shares that may become issuable in the future;
3.To elect four (4) directors to hold office for a one year term and until their successors are elected and qualified or until their earlier incapacity, removal or resignation;
4.Approval of the Amendment to the Akers Bioscience, Inc. 2018 Equity Incentive Plan to increase the total number of shares of common stock authorized for issuance under such plan by 1,042,000, to a total of 1,120,125 shares;
5.To ratify the appointment of Morison Cogen LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
6.Approval, on an advisory basis, of the compensation paid to our named executive officers;
7.Approval, on an advisory basis, of the frequency of future advisory votes on the compensation paid to our named executive officers;
8.Such other matters as may properly come before the Annual Meeting or any adjournment(s) or postponement(s) thereof.
|
| 2020-03-24 |
股东大会：
将于2020-05-07召开股东大会
会议内容 ▼▲
- 1.The election of eight Trustees to hold office until the next Annual Meeting or until their successors are duly elected and qualify;
2.The ratification of the appointment of BDO USA, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2020;
3.The approval, on a non-binding advisory basis, of the compensation of Named Executive Officers as disclosed in the Company's 2020 Proxy Statement in accordance with the compensation rules of the Securities and Exchange Commission
4.To consider and act upon a proposal to approve the Acadia Realty Trust 2020 Share Incentive Plan;
5.Such other business as may properly come before the Annual Meeting.
|
| 2020-02-27 |
除权日：
美东时间 2020-03-30 每股派息0.29美元
|
| 2019-11-12 |
股东大会：
将于2019-12-16召开股东大会
会议内容 ▼▲
- 1.To elect four (4) directors to hold office for a one year term and until their successors are elected and qualified or until their earlier incapacity, removal or resignation;
2.To ratify the appointment of Morison Cogen LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 2019;
3.Such other matters as may properly come before the Annual Meeting or any adjournment(s) or postponement(s) thereof.
|
| 2019-11-05 |
除权日：
美东时间 2019-12-30 每股派息0.29美元
|
| 2019-08-13 |
除权日：
美东时间 2019-09-27 每股派息0.28美元
|
| 2019-05-09 |
除权日：
美东时间 2019-06-27 每股派息0.28美元
|
| 2019-03-26 |
股东大会：
将于2019-05-09召开股东大会
会议内容 ▼▲
- 1.The election of eight Trustees to hold office until the next Annual Meeting or until their successors are duly elected and qualify;
2.The ratification of the appointment of BDO USA, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2019;
3.The approval, on a non-binding advisory basis, of the compensation of Named Executive Officers as disclosed in the Company's 2019 Proxy Statement in accordance with the compensation rules of the Securities and Exchange Commission;
4.Such other business as may properly come before the Annual Meeting.
|
| 2019-02-28 |
除权日：
美东时间 2019-03-28 每股派息0.28美元
|
| 2019-02-05 |
股东大会：
将于2019-03-05召开股东大会
会议内容 ▼▲
- 1.To approve the cancellation of the admission of the Company’s common stock of no par value to trading on AIM, a market operated by London Stock Exchange, and that the directors and officers of the Company be authorized to take all steps which are necessary or desirable in order to effect such cancellation (the “Cancellation Proposal”).
|
| 2018-11-15 |
除权日：
美东时间 2018-12-28 每股派息0.28美元
|
| 2018-11-14 |
股东大会：
将于2018-12-07召开股东大会
会议内容 ▼▲
- 1.To elect three (3) directors to hold office for a one year term and until their successors are elected and qualified or until their earlier incapacity, removal or resignation;
2.To approve the Akers Biosciences, Inc. 2018 Equity Incentive Plan;
3.To ratify the amendments to the Akers Biosciences, Inc. 2013 Incentive Plan;
4.To consider and conduct a non-binding advisory vote on a proposal to approve the Company’s executive compensation;
5.To ratify the appointment by the Audit Committee of the Company’s Board of Directors of Morison Cogen LLP as the Company’s registered public accounting firm for the fiscal year ending December 31, 2018;
6.To transact such other business as may properly come before the Meeting or any adjournment thereof.
|
| 2018-08-07 |
除权日：
美东时间 2018-09-27 每股派息0.27美元
|
| 2018-05-11 |
除权日：
美东时间 2018-06-28 每股派息0.27美元
|
| 2018-03-27 |
股东大会：
将于2018-05-10召开股东大会
会议内容 ▼▲
- 1.The election of eight Trustees to hold office until the next Annual Meeting or until their successors are duly elected and qualified;
2.The ratification of the appointment of BDO USA, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018;
3.The approval, on an advisory basis, of the compensation of Named Executive Officers as disclosed in the Company's 2018 Proxy Statement in accordance with compensation rules of the Securities and Exchange Commission;
4.Such other business as may properly come before the Annual Meeting.
|
| 2018-02-27 |
除权日：
美东时间 2018-03-28 每股派息0.27美元
|
| 2017-11-08 |
除权日：
美东时间 2017-12-28 每股派息0.27美元
|
| 2017-08-10 |
除权日：
美东时间 2017-09-28 每股派息0.26美元
|
| 2017-07-24 |
股东大会：
将于2017-08-07召开股东大会
会议内容 ▼▲
- 1.To elect five (5) directors to hold office for a one year term and until each of their successors are elected and qualified;
2.To ratify the appointment of Morison Cogen LLP as our independent certified public accounting firm for the fiscal year ending December 31, 2017;
3.To approve the adoption of the Akers Biosciences, Inc. 2017 Equity Incentive Plan;
4.To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2017-05-11 |
除权日：
美东时间 2017-06-28 每股派息0.26美元
|
| 2017-03-28 |
股东大会：
将于2017-05-10召开股东大会
会议内容 ▼▲
- 1.The election of eight Trustees to hold office until the next Annual Meeting or until their successors are duly elected and qualified;
2.The ratification of the appointment of BDO USA, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2017;
3.The approval, on an advisory basis, of the compensation of Named Executive Officers as disclosed in the Company's 2017 Proxy Statement in accordance with compensation rules of the Securities and Exchange Commission;
4.To approve an amendment to the Company’s Declaration of Trust to increase the authorized share capital of the Company from 100 million shares of beneficial interest to 200 million shares of beneficial interest;
5.To determine, on an advisory basis, whether the shareholder vote to approve the compensation of the Named Executive Officers, in accordance with compensation rules of the Securities and Exchange Commission, should occur every one, two or three years;
6.Such other business as may properly come before the Annual Meeting.
|
| 2017-03-01 |
除权日：
美东时间 2017-03-29 每股派息0.26美元
|
| 2016-11-14 |
股东大会：
将于2016-12-19召开股东大会
会议内容 ▼▲
- 1. To elect five (5) directors to hold office for a one year term and until each of their successors are elected and qualified;
2. To ratify the appointment of Morison Cogen LLP, as our independent certified public accounting firm for the fiscal year ending December 31, 2016;
3. To consider and conduct a non-binding advisory vote on a proposal to approve the Company’s executive compensation;
4. To transact such other business as may properly come before the Annual Meeting or any postponement or adjournment thereof.
|
| 2016-11-10 |
除权日：
美东时间 2016-12-28 每股派息0.26美元
|
| 2016-11-10 |
除权日：
美东时间 2016-12-28 每股派息0.15美元
|
| 2016-08-10 |
除权日：
美东时间 2016-09-28 每股派息0.25美元
|
| 2016-05-09 |
除权日：
美东时间 2016-06-28 每股派息0.25美元
|
| 2016-03-30 |
股东大会：
将于2016-05-09召开股东大会
会议内容 ▼▲
- 1.The election of eight Trustees to hold office until the next annual meeting and until their successors are duly elected and qualified;
2.The ratification of the appointment of BDO USA, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2016;
3.The approval, on an advisory basis, of the compensation of Named Executive Officers as disclosed in the Company's 2016 Proxy Statement in accordance with compensation rules of the Securities and Exchange Commission;
4.To consider and act upon a proposal to approve the Second Amended and Restated Acadia Realty Trust 2006 Share Incentive Plan;
5.Such other business as may properly come before the Annual Meeting.
|
| 2016-03-18 |
除权日：
美东时间 2016-03-29 每股派息0.25美元
|
| 2015-11-11 |
除权日：
美东时间 2015-12-29 每股派息0.25美元
|
| 2015-11-11 |
除权日：
美东时间 2015-12-29 每股派息0.25美元
|
| 2015-08-12 |
除权日：
美东时间 2015-09-28 每股派息0.24美元
|
| 2015-05-27 |
除权日：
美东时间 2015-06-26 每股派息0.24美元
|
| 2015-03-10 |
除权日：
美东时间 2015-03-27 每股派息0.24美元
|
| 2014-12-05 |
除权日：
美东时间 2014-12-29 每股派息0.30美元
|
| 2014-11-06 |
除权日：
美东时间 2014-12-29 每股派息0.24美元
|
| 2014-08-06 |
除权日：
美东时间 2014-09-26 每股派息0.23美元
|
| 2014-05-14 |
除权日：
美东时间 2014-06-26 每股派息0.23美元
|
| 2014-03-10 |
除权日：
美东时间 2014-03-27 每股派息0.23美元
|
| 2013-11-04 |
除权日：
美东时间 2013-12-27 每股派息0.23美元
|
| 2013-08-06 |
除权日：
美东时间 2013-09-26 每股派息0.21美元
|
| 2013-05-16 |
除权日：
美东时间 2013-06-26 每股派息0.21美元
|
| 2013-02-25 |
除权日：
美东时间 2013-03-26 每股派息0.21美元
|
| 2012-11-13 |
除权日：
美东时间 2012-12-27 每股派息0.18美元
|
| 2012-08-15 |
除权日：
美东时间 2012-09-26 每股派息0.18美元
|
| 2012-06-07 |
除权日：
美东时间 2012-06-27 每股派息0.18美元
|
| 2012-03-22 |
除权日：
美东时间 2012-03-29 每股派息0.18美元
|
| 2011-12-06 |
除权日：
美东时间 2011-12-28 每股派息0.18美元
|
| 2011-08-08 |
除权日：
美东时间 2011-09-28 每股派息0.18美元
|
| 2011-05-10 |
除权日：
美东时间 2011-06-28 每股派息0.18美元
|
| 2011-03-17 |
除权日：
美东时间 2011-03-29 每股派息0.18美元
|
| 2010-11-09 |
除权日：
美东时间 2010-12-29 每股派息0.18美元
|
| 2010-08-26 |
除权日：
美东时间 2010-09-28 每股派息0.18美元
|
| 2010-05-10 |
除权日：
美东时间 2010-06-28 每股派息0.18美元
|